David D. Kim, PhD, is an Assistant Professor of Medicine and Public Health Sciences at the University of Chicago. His interdisciplinary research integrates health economics, policy evaluation, and decision modeling to advance value-based healthcare decision-making. Dr. Kim’s work has focused on defining and measuring the value of health interventions and guiding policies that promote the use of high-value care while discouraging low-value care. He has developed innovative analytical frameworks in economic evaluation and disease simulation models, including a Decision Framework for Assessing Transferability of Economic Evaluation, the Criteria for Health Economic Quality Evaluation (CHEQUE) tool, and the Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) model. His work has been published in leading journals, including JAMA, Annals of Internal Medicine, Health Affairs, and Medical Decision Making, and has received coverage in major media outlets, such as The New York Times and The Washington Post. Dr. Kim serves as a member of the World Health Organization’s Guidelines Development Group for GLP-1RAs for obesity management, the Midwest Comparative Effectiveness Public Advisory Council at the Institute for Clinical and Economic Review (ICER), and as an Associate Method Editor for Annals of Internal Medicine.
University of Washington
Seattle
PhD - Health Economics
2016
University of Michigan
Ann Arbor
MS - Biostatistics
2012
University of Michigan
Ann Arbor
BSE - Biomedical Engineering
2009
How to Fix a Broken Health Care System: Pathways to Maximize Health and Well-being for All.
How to Fix a Broken Health Care System: Pathways to Maximize Health and Well-being for All. Diabetes Care. 2025 Jun 21.
PMID: 40542616
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. JAMA Health Forum. 2025 Apr 04; 6(4):e250905.
PMID: 40279111
Estimated Impact Of Medically Tailored Meals On Health Care Use And Expenditures In 50 US States.
Estimated Impact Of Medically Tailored Meals On Health Care Use And Expenditures In 50 US States. Health Aff (Millwood). 2025 Apr; 44(4):433-442.
PMID: 40193837
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025 Mar 07; 6(3):e245586.
PMID: 40085108
Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data.
Genicular Artery Embolization, Radiofrequency Ablation, and Corticosteroid Therapy for Knee Osteoarthritis: A Cost-Effectiveness Analysis Using Randomized Clinical Trial Data. AJR Am J Roentgenol. 2024 Dec 26; 1-15.
PMID: 39320355
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions.
Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions. Health Qual Life Outcomes. 2024 Sep 02; 22(1):72.
PMID: 39218902
The effects of SNAP emergency allotments on state-level SNAP benefits and enrollment during the COVID-19 pandemic.
The effects of SNAP emergency allotments on state-level SNAP benefits and enrollment during the COVID-19 pandemic. Health Aff Sch. 2024 Sep; 2(9):qxae109.
PMID: 39328393
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau.
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau. Am J Manag Care. 2024 Aug; 30(8):348-350.
PMID: 39146483
Patient-Provider Communication and Access, Use, and Financial Burden of Care.
Patient-Provider Communication and Access, Use, and Financial Burden of Care. Am J Prev Med. 2024 Nov; 67(5):740-745.
PMID: 39002888
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
PMID: 39005006